IHC - CD68

IHC – CD68 Test

The IHC CD68 Test is a specialized immunohistochemistry (IHC) diagnostic test used to detect CD68 protein expression in tissue samples. CD68 is a glycoprotein commonly expressed on macrophages, histiocytes, monocytes, and certain myeloid lineage cells, making it an important biomarker in hematopathology, soft tissue pathology, and inflammatory disease diagnosis.

This test plays a critical role in identifying histiocytic lesions, macrophage-rich tumors, giant cell tumors, myeloid neoplasms, and selected inflammatory disorders. It helps pathologists determine cellular origin and supports differential diagnosis when routine histopathology findings are inconclusive.

The IHC CD68 test is commonly used in evaluating:

• Histiocytic tumors
• Histiocytic sarcoma
• Giant cell tumor
• Myeloid sarcoma
• Granulomatous inflammatory lesions
• Soft tissue tumors requiring macrophage differentiation

The test is performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy or surgical specimens using advanced antibody staining methods. Expert pathologists examine stained tissue microscopically to assess CD68 protein expression and determine the presence of histiocytic or macrophage lineage cells.

CD68 is often used as part of a broader immunophenotyping panel alongside markers such as CD163, CD45, lysozyme, CD1a, S100, and MPO, depending on the suspected diagnosis.

This test is especially valuable for distinguishing histiocytic lesions from lymphoid, epithelial, or mesenchymal tumors, ensuring precise diagnosis and appropriate treatment planning.

Accurate CD68 expression analysis helps oncologists confirm diagnosis, assess prognosis, and guide personalized patient management.

Benefits of the Test

• Detects CD68 protein expression accurately
• Supports histiocytic and macrophage tumor diagnosis
• Helps classify inflammatory and soft tissue lesions
• Assists differential diagnosis
• Improves pathology diagnostic precision
• Supports personalized treatment planning

Why Doctors Recommend This Test

Doctors commonly recommend the CD68 IHC Test when:

• Histiocytic tumor is suspected
• Soft tissue lesion classification is required
• Granulomatous inflammation needs confirmation
• Routine biopsy findings are inconclusive
• Differential diagnosis is necessary
• Myeloid tumor evaluation is required
• Treatment planning depends on exact diagnosis
• Expert pathology confirmation is needed

This test improves diagnostic confidence for accurate disease management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous pathology reports
• Relevant imaging and clinical records
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the CD68 IHC Test is usually 4–7 working days, depending on staining complexity and interpretation requirements.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected histiocytic tumors
• Individuals requiring inflammatory lesion classification
• Patients undergoing soft tissue tumor evaluation
• Individuals with unclear tissue diagnosis
• Oncology patients under specialist care
• Patients requiring advanced immunohistochemistry confirmation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert pathology specialists ensure highly accurate CD68 IHC reports for reliable diagnosis and personalized treatment planning.